Please login to the form below

Not currently logged in
Email:
Password:

Truxima

This page shows the latest Truxima news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

period. A number of biosimilar versions of the drug hit European markets last year, including Celltrion's Truxima, (pictured), marketed by Mundipharma and other firms across the region, and this year

Latest news

  • Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

    This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera. ... With Remsima, we achieved market

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    Novartis’ unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab).

  • Roche faces prospect of second Rituxan biosimilar in US Roche faces prospect of second Rituxan biosimilar in US

    It was the second biosimilar of Roche's drug to be approved in Europe after Celltrion/Mundipharma's Truxima, which also pipped Sandoz to the filing post in the US after

  • Standing out in a crowd Standing out in a crowd

    It followed that this year by gaining approval from the European Commission for the world’s first monoclonal antibody biosimilar of MabTera (rituximab), marketed as Truxima.

  • Sandoz joins Europe's MabThera biosimilar push Sandoz joins Europe's MabThera biosimilar push

    The approval - which comes four months after Celltrion/Mundipharma's Truxima biosimilar was cleared for marketing by the EMA - is for the entire range of indications awarded to MabThera, including ... Truxima claimed the distinction of being the first

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics